BioCryst Pharmaceuticals, Inc. (BCRX)
7.61
-0.07
(-0.91%)
USD |
NASDAQ |
Nov 13, 16:00
7.60
-0.01
(-0.13%)
After-Hours: 19:59
BioCryst Pharmaceuticals EPS Diluted (Quarterly) : 0.1417 for Sept. 30, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 0.1417 |
| June 30, 2026 | 0.2957 |
| March 31, 2026 | -2.980 |
| December 31, 2025 | 1.121 |
| September 30, 2025 | 0.0587 |
| June 30, 2025 | 0.0231 |
| March 31, 2025 | 0.0001 |
| December 31, 2024 | -0.1292 |
| September 30, 2024 | -0.0678 |
| June 30, 2024 | -0.0614 |
| March 31, 2024 | -0.1717 |
| December 31, 2023 | -0.3065 |
| September 30, 2023 | -0.1906 |
| June 30, 2023 | -0.3983 |
| March 31, 2023 | -0.2829 |
| December 31, 2022 | -0.3827 |
| September 30, 2022 | -0.2284 |
| June 30, 2022 | -0.3171 |
| March 31, 2022 | -0.4013 |
| December 31, 2021 | -0.0978 |
| September 30, 2021 | -0.3283 |
| June 30, 2021 | -0.243 |
| March 31, 2021 | -0.3615 |
| December 31, 2020 | -0.3425 |
| September 30, 2020 | -0.2612 |
| Date | Value |
|---|---|
| June 30, 2020 | -0.239 |
| March 31, 2020 | -0.2439 |
| December 31, 2019 | -0.02 |
| September 30, 2019 | -0.3405 |
| June 30, 2019 | -0.341 |
| March 31, 2019 | -0.2819 |
| December 31, 2018 | -0.2498 |
| September 30, 2018 | -0.2808 |
| June 30, 2018 | -0.19 |
| March 31, 2018 | -0.2614 |
| December 31, 2017 | -0.20 |
| September 30, 2017 | -0.18 |
| June 30, 2017 | -0.21 |
| March 31, 2017 | -0.1892 |
| December 31, 2016 | -0.06 |
| September 30, 2016 | -0.16 |
| June 30, 2016 | -0.22 |
| March 31, 2016 | -0.31 |
| December 31, 2015 | -0.25 |
| September 30, 2015 | -0.20 |
| June 30, 2015 | 0.06 |
| March 31, 2015 | -0.21 |
| December 31, 2014 | -0.16 |
| September 30, 2014 | -0.12 |
| June 30, 2014 | -0.23 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Halozyme Therapeutics, Inc. | 2.015 |
| Neurocrine Biosciences, Inc. | 1.963 |
| Agenus, Inc. | 0.0183 |
| Amgen, Inc. | 7.077 |
| Anika Therapeutics, Inc. | -0.0232 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | 37.92M |
| Revenue (Quarterly) | 180.29M |
| Total Expenses (Quarterly) | 142.38M |
| Enterprise Value | 2.402B |
| Gross Profit Margin (Quarterly) | 98.99% |
| Profit Margin (Quarterly) | 21.03% |
| Earnings Yield | -18.67% |
| Operating Earnings Yield | 21.59% |
| Normalized Earnings Yield | 8.314 |